BiomX (PHGE) Cash from Investing Activities (2018 - 2026)
BiomX (PHGE) posted Cash from Investing Activities of -$996000.0 for Q1 2026, down 99700.0% sequentially from $1000.0 in Q4 2025, and down 2052.94% YoY from $51000.0 in Q1 2025.
BiomX (PHGE) Cash from Investing Activities (2018 - 2026) Analysis & Trends
BiomX has reported Cash from Investing Activities for 9 years, with the latest figure at -$996000.0 in Q1 2026.
- Quarterly Cash from Investing Activities fell 2052.94% year-over-year to -$996000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$939000.0 (down 1011.65% YoY) and the FY2025 annual result came in at $108000.0, down 84.9% from the prior year.
- Cash from Investing Activities retreated to -$996000.0 in Q1 2026 per PHGE's latest filing, from $1000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $4.5 million in Q3 2022 and troughed at -$10.0 million in Q1 2022.
- A 5-year average of -$62000.0 and a median of $0.0 in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2024 and 2026: Cash from Investing Activities surged 5500.0% in 2024, then sank 2052.94% in 2026.
- Over 5 years, Cash from Investing Activities stood at $1.5 million in 2022, then plunged by 100.41% to -$6000.0 in 2023, then surged by 83.33% to -$1000.0 in 2024, then surged by 200.0% to $1000.0 in 2025, then sank by 99700.0% to -$996000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$996000.0, $1000.0, and -$2000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | BiomX | 351,774.34 | -816,225.66 | - | -996,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -996,000.00 |
| Mar 31, 2026 | -996,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Jun 30, 2025 | 58,000.00 |
| Jun 30, 2025 | 58,000.00 |
| Mar 31, 2025 | 51,000.00 |
| Mar 31, 2025 | 51,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | 54,000.00 |
| Jun 30, 2024 | 54,000.00 |
| Dec 31, 2023 | -6,000.00 |
| Dec 31, 2023 | -6,000.00 |
| Sep 30, 2023 | -32,000.00 |
| Sep 30, 2023 | -32,000.00 |